Page last updated: 2024-12-10

bis(maltolato)oxovanadium(iv)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bis(maltolato)oxovanadium(IV): a hypoglycemic agentt; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3035454
SCHEMBL ID12489157
MeSH IDM0200450

Synonyms (15)

Synonym
bmov(iv)
vanadium, bis(3-hydroxy-2-methyl-4h-pyran-4-onato-o3,o4)oxo-, (sp-5-31)-
bis(maltolato)oxovanadium(iv)
38213-69-3
unii-ha933d78yw
ha933d78yw ,
SCHEMBL12489157
DTXSID50191593
AKOS030240247
bis((2-methyl-4-oxo-pyran-3-yl)oxy)-oxo-vanadium
bis(maltolato)oxovanadium
vo(ma)2
2-methyl-4-oxopyran-3-olate;oxovanadium(2+)
2-methyl-4-oxopyran-3-olate
bis maltolato oxovanadium,bis(maltolato)oxovanadium (iv),

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic investigation was performed using non-diabetic rats."( The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Chen, GH; Lu, WL; Zhang, Q; Zhang, SQ; Zhong, XY, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" We compared the ability of bis(maltolato)oxovanadium(IV) (BMOV), an orally bioavailable organo-vanadium compound, and rosiglitazone maleate (RSG), a known insulin sensitizer, to prevent development of diabetes in Zucker diabetic fatty (ZDF) rats."( A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
Davis, MG; Downs, TR; Gerwe, GS; Kasibhatla, B; Lange, JS; Peters, KG; Winter, CL, 2005
)
0.87
" The average absolute bioavailability for intragastric administration at a single dose of 3, 6 and 12 mgV/kg was 28."( The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Chen, GH; Lu, WL; Zhang, Q; Zhang, SQ; Zhong, XY, 2008
)
0.35
" These bis-ligand oxovanadium(IV) (VOL(2)) compounds have a clear advantage over inorganic vanadyl sulfate in terms of bioavailability and pharmaceutical efficacy."( Vanadium treatment of type 2 diabetes: a view to the future.
LeBel, C; Lichter, J; McNeill, JH; Orvig, C; Scaife, MC; Thompson, KH, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" An oral dose-response curve showed that BMOV was 2 to 3 times as potent as vanadyl sulfate."( Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
McNeill, JH; Orvig, C; Yuen, VG, 1995
)
0.53
" In conclusion, at the present dosing levels and administration routes, BMOV was effective in lowering plasma glucose levels in diabetic rats."( The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Chen, GH; Lu, WL; Zhang, Q; Zhang, SQ; Zhong, XY, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (72)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's16 (22.22)18.2507
2000's40 (55.56)29.6817
2010's13 (18.06)24.3611
2020's3 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.98 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index20.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.33%)5.53%
Reviews2 (2.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other72 (96.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]